Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results Webcast and Conference Call Today at 5:00 p.m. Eastern Time PR Newswire JERSEY CITY, N.J., Nov. 1, 2012 JERSEY CITY, N.J., Nov. 1, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company's financial results for the quarter ended September 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) Third Quarter 2012 Financial Highlights: oDIFICID® gross sales in the U.S. and Canada of $18.7 million and net sales of $16.0 million, represent increases of 3.9% and 4.9% over the second quarter, respectively oEstimated DIFICID ex-wholesaler and ex-specialty pharmacy treatments shipped in the third quarter to U.S. and Canadian purchasing customers, including hospitals, retail pharmacies and long-term care facilities, increased by approximately 7.2% compared to the second quarter oContract revenues from collaborations, which include royalties and bulk pharmaceutical sales, were $1.9 million oTotal revenues were $17.9 million oCash, cash equivalents and short-term investments at September 30 totaled $98.2 million oNet loss for the third quarter was $26.8 million, or $0.56 per share Financial Overview Total revenues for the three months ended September 30, 2012 and 2011 were $17.9 million and $11.1 million, respectively, an increase of $6.8 million. In the three months ended September 30, 2012, we recognized $16.0 million of net product sales of DIFICID in the U.S. and Canada. We recognize product sales of DIFICID upon delivery of product to our wholesalers and specialty pharmacies. In addition, we recognized $1.9 million in contract revenue under our collaborations with Astellas Pharmaceuticals Europe Ltd., Astellas Pharma, Inc. and Specialized Therapeutics Australia, Pty. Ltd. We reported a net loss for the third quarter of 2012 of $26.8 million, or $0.56 per share on both a basic and diluted basis, as compared to a net loss for the third quarter 2011 of $26.4 million, or $0.57 per share on both a basic and diluted basis. Research and development expense for the three months ended September 30, 2012 and 2011 was $10.7 million and $10.4 million, respectively, an increase of $0.3 million. Selling, general and administrative expense for the three months ended September 30, 2012 and 2011 was $26.4 million and $24.0 million, respectively, an increase of $2.4 million. The increase was due to higher salary expense and increased legal and other consulting services. Co-promotion expenses with Cubist for the three months ended September 30, 2012 and 2011 were $4.4 million and $2.9 million, respectively, an increase of $1.4 million. The increase represented certain profit-sharing expenses earned by Cubist under our April 2011 DIFICID co-promotion agreement. As ofSeptember 30, 2012, we held cash, cash equivalents and short-term investments of$98.2 million. This does not include proceeds from an agreement announced October 8, 2012 to sell our stake in Optimer Biotechnology, Inc. (OBI). The sale is expected to result in net proceeds of $59.8 million and was structured to close in two tranches. The first closing took place on October 19, 2012 and the second closing is expected to take place in the first quarter of 2013. We had 47.7 million shares outstanding on September 30, 2012. DIFICID Update "Over the last two quarters, we have expanded global availability of fidaxomicin through the launch of DIFICLIR in Europe with our partner Astellas Pharma Europe,our own launch of DIFICID in Canada and the continued negotiation of new agreements," continued Mr. Lichtinger. "As part of our life-cycle management strategy, we are pursuing new indications to expand the utility of DIFICID for patients in need. This morning, we announced the dosing of the first patient in our Phase 3b clinical trial evaluating DIFICID as a prophylactic in patients undergoing hematopoietic stem cell transplant, a population with a high prevalence of CDAD and without any FDA-approved preventative treatments for the disease." DIFICID net sales of $16.0 million in the third quarter of 2012 reflected a 4.9% increase over the second quarter of 2012 and a 51.5% increase over the prior year period. Gross sales to U.S. and Canadian wholesalers and specialty pharmacies of $18.7 million in the third quarter of 2012 represented 6,692 treatments shipped, and a 3.9% increase over the $18.0 million in gross sales for the second quarter of 2012 and a 53.7% increase from the prior-year period. Further, approximately 6,600 DIFICID treatments were shipped from wholesalers and specialty pharmacies to U.S. and Canadian purchasing customers, including hospitals, retail pharmacies and long-term care facilities, in the third quarter, a 7.2% increase over the prior quarter and an increase of 131.7% over the prior year period. Additionally, as of September 30, 2012: oInventory levels at wholesalers remain within the range of 14 to 28 days of demand oApproximately 2,360 U.S. hospitals had ordered DIFICID oApproximately 79% of U.S. hospitals covered by Optimer have reordered DIFICID oThe number of target hospitals including DIFICID on their formularies was approximately 960 oApproximately 95% of all commercial lives and 80% of Medicare Part D lives in the United States had formulary payor access to DIFICID, bringing the total percent of insured patients with covered access to 88%. DIFICID Strategic Update "In October we launched new initiatives to educate the hospital market about our recently-instituted discount program and on DIFICID RxAssist, and we are optimistic that these efforts will help facilitate patient access to DIFICID while in the hospital and upon discharge. We have received positive initial feedback from hospitals to our initiatives since their introduction last month," said Pedro Lichtinger, President and CEO of Optimer. "Separately, we also are engaging in efforts to educate customers about the NTAP program, which can provide an additional reimbursement to eligible hospitals for qualifying Medicare Part A in-patient cases where DIFICID is utilized. And, in addition to our strategic initiatives, we continue educational efforts to provide information to customers on the burden of CDI, providing data that help address gaps in evidence regarding readmissions and disease burden." Conference Call and Webcast Optimer will host a conference call and webcast to discuss its third quarter financial results and to provide a corporate update today at5:00 p.m. Eastern time (2:00 p.m. Pacific time). The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call." The conference call will be webcast live under the Investors section of Optimer's website atwww.optimerpharma.com, where it and any accompanying slides will be archived for 30 days following the call. AboutClostridium difficile-associated Diarrhea (CDAD) Clostridium difficileinfection (CDI) is a serious illness resulting from infection of the inner lining of the colon byC. difficilebacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.Clostridium difficile-associated diarrhea is the most common symptom of CDI. In recent years,C. difficilehas surpassed methicillin-resistantStaphylococcus aureus(MRSA) as the leading cause of healthcare-acquired infections in community hospitals. Patients typically develop CDAD from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, possibly allowingC. difficilebacteria to flourish. About DIFICID® (fidaxomicin) Tablets DIFICID is the first macrolide antibacterial drug indicated forClostridium difficile-associated diarrhea (CDAD) to be approved in over 25 years in the U.S. It is indicated for the treatment of CDAD in adults 18 years of age or older. DIFICID is administered in 200 mg tablets given orally twice daily. Important Safety Information for DIFICID DIFICID is contraindicated in patients with hypersensitivity to fidaxomicin or to any of the excipients in the formulation. DIFICID should not be used for systemic infections. Only use DIFICID for infection proven or strongly suspected to be caused byC. difficile. Prescribing DIFICID in the absence of a proven or strongly suspectedC. difficileinfection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria. The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%) and neutropenia (2%). Please visitwww.DIFICID.comor call 855-DIFICID (343-4243) for full prescribing information for DIFICID. AboutOptimer Pharmaceuticals Optimer Pharmaceuticals, Inc.is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, anFDA-approved macrolide antibacterial drug for the treatment ofClostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in theEuropean Unionwhere its partner,Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™. The Company is exploring marketing authorization in other parts of the world whereC. difficilehas emerged as a serious health problem, includingAsia. Additional information can be found at http://www.optimerpharma.com. Forward-Looking Statements Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to Optimer's initiatives to increase patient access to DIFICID, the timing of the second closing of Optimer's sale of its remaining equity in OBI, Optimer's pursuit of new indications for DIFICID and Optimer's on-going educations efforts regarding its patient access initiatives and the burden of CDI. Words such as "believes", "would", "anticipates", "plans", "expects", "may", "intend", "will", and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management's expectations on the date of this releaseand Optimer undertakes no obligation to update or revise these statements, except as may be required by law. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's businessincluding, without limitation, risks relating to:Optimer'sability to continue driving adoption and use of DIFICID, DIFICID's ability to compete with cheaper generic alternatives, whether healthcare professionals will prescribe DIFICID,the extent to which DIFICID will be accepted on additional hospital formularies and the timing of hospital formulary decisions, whether Optimer's patient access initiatives will result in additional DIFICID prescriptions in the hospital or retail markets, whether Rx Assist is utilized and whether it will facilitate access to DIFICID, whether and when the closing conditions applicable to the second closing of Optimer's sale of OBI equity will be satisfied, and other risks detailed inOptimer'sfilings with theSecurities and Exchange Commission. Contacts Optimer Pharmaceuticals, Inc. David Walsey, Vice President, Investor Relations and Corporate Communications (858) 964-3418 Canale Communications, Inc. Jason I. Spark, Senior Vice President (619) 849-6005 OPTIMER and DIFICID are trademarks ofOptimer Pharmaceuticals, Inc.All other trademarks are the property of their respective owners. Optimer Pharmaceuticals, Inc. Consolidated Statements of Operations and Comprehensive Loss (unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2012 2011 2012 2011 Revenues: Product sales, net $ $ $ $ 15,983,575 10,551,820 45,596,203 10,551,820 Contract revenue 1,891,959 - 36,417,444 69,165,000 Other - 500,264 2,106 645,197 Total revenues 17,875,534 11,052,084 82,015,753 80,362,017 Cost and expenses: Cost of product 1,421,267 615,955 5,974,858 615,955 sales Cost of contract 1,213,473 - 2,957,655 4,273,532 revenue Research and 10,710,251 10,405,459 33,335,435 29,074,229 development Selling, general and 26,444,831 24,015,928 80,824,042 50,582,925 administrative Co-promotion 4,357,463 2,928,760 19,440,629 2,928,760 expenses with Cubist Total operating 44,147,285 37,966,102 142,532,619 87,475,401 expenses Loss from operations (26,271,751) (26,914,018) (60,516,866) (7,113,384) Gain on de-consolidation of - - 23,782,229 - OBI Equity in net loss of (694,433) - (1,849,254) - OBI Interest income and 195,504 108,431 316,209 227,533 other, net Consolidated net (26,770,680) (26,805,587) (38,267,682) (6,885,851) loss Net loss attributable to non-controlling - 378,916 280,344 1,353,204 interest Net loss attributable $ $ $ $ to Optimer (26,770,680) (26,426,671) (37,987,338) (5,532,647) Pharmaceuticals, Inc. Net loss per share - $ $ $ $ basic and diluted (0.56) (0.57) (0.80) (0.12) Weighted average number of shares used to compute net loss per share - 47,619,006 46,624,390 47,252,123 45,269,621 basic and diluted Comprehensive loss $ $ $ $ (27,353,113) (27,976,402) (37,437,798) (7,533,274) Optimer Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets September 30, December 31, 2012 2011 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 86,872,487 $ 31,787,512 Short-term investments 11,339,862 78,791,066 Trade accounts receivable, 6,240,170 6,563,645 net Accounts receivable, other 1,675,091 52,289,290 Inventory 13,279,904 3,947,380 Prepaid expenses and other 1,761,757 3,781,830 current assets Total current assets 121,169,271 177,160,723 Equity investment in OBI 28,319,359 - Property, equipment and other, 3,990,520 2,590,715 net Long-term investments 882,000 882,000 Other assets 1,420,841 1,389,734 Total assets $ 155,781,991 $ 182,023,172 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ $ 9,601,742 9,860,462 Accrued expenses 19,447,265 21,447,544 Deferred revenue 154,416 - Total current liabilities 29,203,423 31,308,006 Deferred rent 227,337 151,141 Stockholders' equity 126,351,231 150,564,025 Total liabilities and $ 155,781,991 $ 182,023,172 stockholders' equity SOURCE Optimer Pharmaceuticals, Inc. Website: http://www.optimerpharma.com
Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
Press spacebar to pause and continue. Press esc to stop.